Clonal autoantibodies identify microbial antigen as trigger of autoreactive B cells in systemic sclerosis
Authors:
- Sam NeppelenbroekSNSam Neppelenbroek
- Sophie I.E. LiemSLSophie I.E. Liem
- Theo van LaarTLTheo van Laar
- Eva M. HoekstraEHEva M. Hoekstra
- Corrie M. WortelCWCorrie M. Wortel
- E.W. Nivine LevarhtELE.W. Nivine Levarht
- Cynthia M. FehresCFCynthia M. Fehres
- Nynke H. DekkerNDNynke H. Dekker
- Jeska K. de Vries-BouwstraJVJeska K. de Vries-Bouwstra
- René E.M. ToesRTRené E.M. Toes
- Hans U. SchererHSHans U. Scherer
Preprint
Abstract
Objectives: Transformative observations demonstrate unprecedented success of B cell-depleting interventions in many human autoimmune diseases, calling for a deeper understanding of the triggers leading to B cell-mediated autoimmunity and its perpetuation in human disease. Here, we investigated whether the autoreactive B cell response targeting human topoisomerase 1 (TOP1), a hallmark of systemic sclerosis, could cross-react with TOP1 of microbial origin. Methods: Homologies between human and microbial TOP1 were analyzed using Foldseek. TOP1-reactive monoclonal antibodies from patient-derived, human TOP1-reactive B cell receptors were generated and assessed for reactivity against human TOP1 and TOP1 from a prototypic yeast, Saccharomyces cerevisiae ( S. cerevisiae ). Reactivity of polyclonal serum IgG from anti-TOP1 autoantibody (ATA) + , anti-centromere autoantibody (ACA) + SSc patients and healthy donors (HDs) was tested. Finally, B cell lines were generated expressing human ATA to study B cell activation upon antigenic stimulation. Results: Structural homologues of human TOP1 were found in many microbes, particularly in fungi. Taking TOP1 from S. cerevisiae as a prototype, microbial TOP1 was recognized by polyclonal patient IgG and by several monoclonal ATAs. Importantly, S. cerevisiae TOP1 also activated B cells expressing a patient-derived, human TOP1-reactive B cell receptor. Patients affected by interstitial lung disease most frequently showed recognition of microbial TOP1. Conclusions: These findings identify fungi as potential drivers of immune dysregulation in human autoimmunity, specifically in SSc, highlighting microbial antigen cross-reactive cells as important therapeutic targets. Moreover, these data provide first functional evidence for a breach of B cell tolerance against human TOP1 triggered by cross-reactivity to fungal TOP1.Keywords
This publication has 44 references indexed in Scilit:
- Geographic Clustering of Systemic Sclerosis in Areas of Environmental PollutionArthritis Care & Research, 2025
- Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosisCell, 2024
- Human gut mycobiota tune immunity via CARD9-dependent induction of anti-fungal IgG antibodiesCell, 2021
- Association of Anti–Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti–Topoisomerase I–Positive Systemic SclerosisArthritis & Rheumatology, 2020
- Using Autoantibodies and Cutaneous Subset to Develop Outcome‐Based Disease Classification in Systemic SclerosisArthritis & Rheumatology, 2019
- Pathogenic Autoreactive T and B Cells Cross-React with Mimotopes Expressed by a Common Human Gut Commensal to Trigger AutoimmunityCell Host & Microbe, 2019
- Commensal Fungi in Health and DiseaseCell Host & Microbe, 2017
- Association of Systemic Sclerosis With a Unique Colonic Microbial ConsortiumArthritis & Rheumatology, 2016
- Evidence‐based guidelines for the use of immunologic tests: Anticentromere, Scl‐70, and nucleolar antibodiesArthritis Care & Research, 2003
- Correlation of serum anti‐DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosisArthritis & Rheumatism, 2003